---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-268173"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T03:05:53.157776+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Taysha Gene Therapies appoints Alison Long to Board; Kathleen Reape resigns

## Summary
- Kathleen Reape resigns from Board effective Nov 1, 2023, per employer governance rules; no disagreement with company.
- Alison Long appointed as Class I director effective Nov 1, 2023, and chair of Clinical and Science Committee.
- Long also appointed to Compensation and Nominating & Corporate Governance Committees.
- Long receives initial stock option for 43,800 shares vesting over 36 months plus annual retainers ($35k director, extra committee fees).
- Long currently CMO of Flightpath Biosciences (consulting) and Clinical Lead of Enigma Biomedical Group; previously CMO at Anokion, Kaleido.

## SEC filing metadata
- accession: 0001193125-23-268173
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523268173/0001193125-23-268173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523268173/d556180d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-268173
- JSON: https://secwatch.observer/filing/0001193125-23-268173.json
- Plain text: https://secwatch.observer/filing/0001193125-23-268173.txt

## Key facts
- Executive change
  Alison Long was appointed as Director at Taysha Gene Therapies, Inc..
  - Action: appointed
  - Role: Director
  source text: On October 30, 2023, the Board appointed Alison Long to serve as a director of the Company, effective immediately following Dr. Reape’s resignation (the “ Effective Time ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523268173/0001193125-23-268173-index.htm
- Executive change
  Kathleen Reape resigned as Director at Taysha Gene Therapies, Inc..
  - Action: resigned
  - Role: Director
  source text: Kathleen Reape provided notice to the board of directors (the “ Board ”) of Taysha Gene Therapies, Inc. (the “C ompany ”) of her decision to resign from the Board and all committees thereof, effective November 1, 2023, in accordance with the governance guidelines of Dr. Reape’s employer and not as a result of any disagreement with the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523268173/0001193125-23-268173-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.